All Stories

  1. Therapeutic treatment with a novel hypoxia-inducible factor hydroxylase inhibitor (TRC160334) ameliorates murine colitis

    Article • Clinical and Experimental Gastroenterology, January 2014, Taylor & Francis

    Dr Shitalkumar P Zambad, Ram Gupta

  2. TRC210258, a novel TGR5 agonist, reduces glycemic and dyslipidemic cardiovascular risk in animal models of diabesity

    Article • Diabetes Metabolic Syndrome and Obesity, December 2013, Taylor & Francis

    Mr Anoop Nath Mathur, Dr Shitalkumar P Zambad

  3. The Evolving Face of Heart Failure Associated with Elevated Cardio-Metabolic Risk Factors

    Article • February 2012, IntechOpen

    Dr Shitalkumar P Zambad

  4. TRC150094 attenuates progression of nontraditional cardiovascular risk factors associated with obesity and type 2 diabetes in obese ZSF1 rats

    Article • Diabetes Metabolic Syndrome and Obesity, January 2011, Taylor & Francis

    Dr Shitalkumar P Zambad, Ram Gupta

  5. TRC150094 attenuates progression of nontraditional cardiovascular risk factors associated with obesity and type 2 diabetes in obese ZSF1 rats

    Article • Diabetes Metabolic Syndrome and Obesity, January 2011, Dove Medical Press

    Dr Shitalkumar P Zambad

  6. TRC150094, a novel functional analog of iodothyronines, reduces adiposity by increasing energy expenditure and fatty acid oxidation in rats receiving a high‐fat diet

    Article • The FASEB Journal, May 2010, Wiley

    Dr Shitalkumar P Zambad

  7. Novel N-substituted 4-hydrazino piperidine derivative as a dipeptidyl peptidase IV inhibitor

    Article • Bioorganic & Medicinal Chemistry Letters, September 2009, Elsevier

    Dr Shitalkumar P Zambad

  8. Synthesis of spiro[chroman-2,4′-piperidin]-4-one derivatives as acetyl-CoA carboxylase inhibitors

    Article • Bioorganic & Medicinal Chemistry Letters, February 2009, Elsevier

    Dr Shitalkumar P Zambad